Mid-March 2026: Peptide Sciences Is Gone, the FDA Hasn't Moved, and the Grey Market Is Collapsing
Peptide Sciences shuts down. The FDA still hasn't published reclassification. The SAFE Drugs Act threatens the RUO model.
Evidence: expert analysis
Independent Peptide Analysis
We don't sell peptides.
We tell you the truth about them.
Evidence-based analysis, vendor accountability, and honest guidance in a market flooded with marketing claims. No vendor sponsorship. No pay-for-play reviews.
Latest Intelligence
View all analysis →CJC-1295 + Ipamorelin: The Grey Market's Most Popular GH Stack Has Zero Published Evidence
Deep analysis of CJC-1295 and ipamorelin — the most used GH secretagogue stack. Mechanism, evidence gaps, and what community protocols actually rest on.
Evidence: animal only
March 2026 Peptide Roundup: RFK Jr. Orders Reclassification, Hims & Hers Enters the Market, and Peptides Hit Prime Time
RFK Jr. announces reclassification of 14 Category 2 peptides on Joe Rogan. Hims & Hers confirms peptide line. HIMS stock surges.
Evidence: expert analysis
February 2026 Peptide Market Roundup: MIT Technology Review, RFK Jr., and the Regulatory Tug-of-War
Monthly roundup: MIT Technology Review's peptide feature, RFK Jr.'s FDA influence, Chinese import crackdown, and regulatory uncertainty.
Evidence: expert analysis
Sermorelin + Testosterone: The Evidence Behind the 'Synergy' Claim
Evidence-based analysis of sermorelin + testosterone therapy. What studies show about GH-testosterone synergy and body composition.
Evidence: expert analysis
The FDA's Peptide Crackdown: A Complete Timeline
Timeline of FDA enforcement actions against peptide vendors from 2023-2026: warning letters, criminal cases, and regulatory changes.
Evidence: well established
Vendor Report Card
Oral BPC-157 vendors rated on transparency, third-party testing, value, and regulatory compliance. Updated quarterly.
A-
Science.bio (Closed)
View full report → Transparency 95
Testing 90
Value 70
Compliance 40
B+
Peptide Partners
View full report → Transparency 80
Testing 90
Value 55
Compliance 65
B
Eternal Peptides
View full report → Transparency 70
Testing 80
Value 55
Compliance 60
B
Verified Peptides
View full report → Transparency 75
Testing 75
Value 55
Compliance 60
Ratings reflect our independent analysis. Vendors cannot pay to improve their scores. See our methodology.
Peptide Knowledge Base
Evidence-rated profiles for every major peptide. What the research shows, what it doesn't, and what vendors won't tell you.
Stay Informed. Stay Independent.
Weekly analysis of the peptide market: regulatory changes, vendor evaluations, research updates, and the news that matters. Zero vendor influence.